Ulrich Thienel

Ulrich Thienel

Company: ReAlta Life Sciences

Job title: Chief Executive Officer

Seminars:

RLS-0071: Dual Target Inhibition in Support of Hypoxic Ischemic Encephalopathy 11:30 am

RLS-0071 is a novel, dual-targeting peptide with upstream control of inflammatory pathways. Mutually supportive inhibition of complement and cellular inflammatory processes support lead candidate RLS- 0071 development in hypoxic ischemic encephalopathy Discussing the Phase 2 clinical trial in progress assessing safety, pharmacokinetics and pharmacodynamic biomarkers planned in HIE Demonstrating a clean safety profile in Phase…Read more

day: Track B - Day 1 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.